Ligation News and Research

RSS

Newly discovered cell type makes survivors of sepsis more vulnerable to infections

Sepsis is the leading cause of death in Brazil's intensive care units (ICUs). Among patients who progress to the severe form of the disease, 40% die, and the survivors often suffer from cardiovascular and neurological complications, as well as a significant decline in immunity lasting for years after they are discharged from hospital.

2 Sep 2021

SARS-CoV-2 destabilizes host RNA to improve fitness

In a study recently published in the journal Nature Communications, scientists have mapped the interactions between SARS-CoV-2 RNA and host RNA. They have observed that the virus heavily methylates its genome using the methylation machinery of the host RNA, leading to an improvement in viral fitness.

27 Aug 2021

Research suggests toll-like receptor 4 appears to play role in severe COVID

A group of researchers re-evaluated their previously proposed hypothesis, which stated that the TLR4 activated by the spike glycoprotein S1 domain increases ACE2 expression and, thereby, aids in COVID-19 infection.

16 Aug 2021

VirtaMed launches surgical gynecology simulation suite

VirtaMed has the world leading validated simulator for hysteroscopy training, and an innovative solution for the acquisition of laparoscopic skills.

From VirtaMed 2 Feb 2021

The structure dynamics of the SARS-CoV-2 genome in cells, cell lysates and virions

Now, a new preprint research paper posted to the bioRxiv server describes the structures observed during the lifecycle of the RNA virus in terms of both canonical and alternative structures, RNA-RNA interactions, and replication regulation.

19 Jan 2021

FASLG gene may drive cytokine-linked adverse COVID-19 outcomes with age

A new study published on the preprint server bioRxiv in December 2020 reveals the role played by certain genetic factors in this group, in particular the FASLG gene belonging to the tumor necrosis factor (TNF) family.

8 Dec 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

DNase coated melanin-like nanospheres for sepsis treatment in severe COVID

As the treatment of severe COVID-19 is very difficult, the researchers from the Korea Research Institute of Biosciences and Biotechnology (KRIBB) suggested that DNase-1 can be utilized to dissolve the neutrophil extracellular traps (NETs), hence halting the further progression of COVID-19.

27 Oct 2020

A new technology to diagnose COVID-19 in just 30 minutes

The year 2020 can be summarized simply by one word - COVID-19 - as it was the culprit that froze the entire world. For more than 8 months so far, movement between nations has been paralyzed all because there are no means to prevent or treat the virus and the diagnosis takes long.

5 Oct 2020

Hospital merger in Washington state stokes fears about Catholic limits on care

The proposed merger of a well-regarded secular hospital system and a larger Roman Catholic system in Washington state has triggered new alarms about religious restrictions on patients' access to care.

3 Aug 2020

Study reveals multiple characteristics of HIV-1-producing cells in vivo

For eradication of HIV-1 infection, it is important to elucidate the detailed features and heterogeneity of HIV-1-infected cells in vivo.

29 Jul 2020

Analysis of the SARS-CoV-2 proteome via visual tools

Now, a new study published on the preprint server bioRxiv* in July 2020 shows how this can be advanced at a greater speed by combining experimental results with homology models obtained by high-throughput pipelines. This will help produce new hypotheses that will show novel druggable targets for effective drug development.

21 Jul 2020

Study provides new insights on mechanisms that promote cancer

Like subway com muters on a crowded train, cells generally prefer not to be packed in too tightly. In fact, they have set up mechanisms to avoid this, a phenomenon called "contact inhibition." A hallmark of cancer cells is that they lack this contact inhibition, and instead become pushy, facilitating their spread.

14 May 2020

Study provides more insight into the initiation and progression of human cancers

Volume 11, Issue 18 of @Oncotarget Clinical implications of chromatin accessibility assessed by ATAC-seq profiling in human cancers especially in a large patient cohort is largely unknown.

6 May 2020

Updated colorectal cancer screening recommendations released

Patients at average risk of colorectal cancer who have a normal colonoscopy do not need to repeat screening for 10 years.

18 Feb 2020

Uterine balloon tamponade is almost 86% effective in preventing maternal mortality from hemorrhaging

According to the World Health Organization's latest statistics, from 2017, more than 800 women around the world die every day from preventable causes related to pregnancy and childbirth -- the vast majority of them in resource-poor areas.

6 Jan 2020

New radiotracer can provide insights into how the heart recovers after myocardial infarction

Insights into how the heart recovers after myocardial infarction (heart attack) can be obtained with a new radiotracer that targets fibroblast activity prior to it causing permanent damage.

2 Jan 2020

€7.6 million ERC Synergy grant to support research on molecular mechanisms of viral infection

The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy. The funding amounts to 7.6 million euros.

11 Oct 2019

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis.

26 Sep 2019

IDT announces significant NGS portfolio expansion

Demonstrating its advocacy for genomics research, Integrated DNA Technologies announces a significant expansion to its NGS portfolio.

From Integrated DNA Technologies 10 May 2019